MedPath

Connectivity of a network associated with rest and inhibition of responses under the influence of atomoxetine/placebo in patients with attention-deficits/hyperactivity disorder-a pharmacological fMRTI study including a scan measuring brain activity while participants are in a resting state and while performing an inhibitory control task

Phase 1
Conditions
Patients with Attention-Deficit/Hyperactivity Disorders (ADHD)
Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
Registration Number
EUCTR2013-002386-18-DE
Lead Sponsor
RWTH Aachen Clinical Trials Center Aachen (CTC-A)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Male
Target Recruitment
52
Inclusion Criteria

Male
Age 18-45 years
Diagnosis of ADHD (patients) or no axis I disorder (controls) according the DSM IV
No substance abuse/ dependency
Understanding of the study information and declaration of agreement
Ability to read, understand and speak German
No severe medical disorders
No risk for suicide

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 52
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Drug dependence or the a positive drug screening
Other Severe physical disorders
Current pharmacological therapy because of another psychiatric disorder
Risk for seizure or cardiac problems
Impaired liver and renal function
Significant deviations in regard to clinical chemistry, haematology or EKG
Relationship of dependency with the sponsor or the investigator
Unable to keep to the study protocol
Known Intolerance of the study medication
fMRI scanner incompatibility

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath